Greg Williams

Greg Williams

| This email address is being protected from spambots. You need JavaScript enabled to view it.
Research Editor, UAB News
(205) 975-3914
gdw@uab.edu

Williams is responsible for helping to further burnish the national reputation of the UAB basic science enterprise, as well as for promoting novel research efforts across all university disciplines. He develops news and feature content for delivery through print and online media, and engages with social media communities formed around common interests relevant to the UAB AMC 21 Research Strategic Plan. Williams is a graduate of the Medill School of Journalism at Northwestern University, and previously worked as senior science editor at the University of Rochester Medical Center in New York State. 

Beats include: Biochemistry and Molecular Genetics, Biomedical Engineering, Cell Biology, Microbiology, Physiology and Biophysics, UAB Research Foundation
Molecular events that form such “reward memories” appear to differ from those created by drug addiction, despite the popular theory that addiction hijacks normal reward pathways.
Discovery leads researchers to redouble efforts to design a new class of drugs to treat diabetes.
Can smell tests reveal brain changes that are precursors to Parkinson's? Research podcast with David Standaert, M.D., Ph.D.
Etty (Tika) Benveniste, Ph.D., chair of the Department of Cell, Integrative and Developmental Biology, has been elected president of the American Society of Neurochemistry, with term running through 2015.
The Department of Cell, Integrative and Developmental Biology has recruited two new faculty members.
Studies in recent years had suggested that cilia regulate vital processes including growth, appetite, mood, healing and vision.
In this preliminary analysis, the first human study treatment neither built up in organs nor destroyed the bone marrow’s ability to make blood cells.
UAB Neurology study adds to evidence that massive, second-wave reaction kills nerve cells.
The finding may help to avert more of the bleeds and blood clots that come when a patient’s starting dose misses the drug’s narrow safety window.
Work may provide insight into drug design for autism, movement disorders.
Page 2 of 4